Quince Therapeutics, Inc.
QNCX
$0.9905
-$0.0095-0.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -12.46M | -5.49M | -27.73M | -11.15M | -8.89M |
| Total Depreciation and Amortization | 16.00K | 86.00K | 44.00K | 40.00K | 304.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.00M | -1.70M | 20.37M | 3.56M | 2.26M |
| Change in Net Operating Assets | 1.90M | -152.00K | -1.42M | -805.00K | 250.00K |
| Cash from Operations | -7.55M | -7.26M | -8.74M | -8.35M | -6.08M |
| Capital Expenditure | -133.00K | -46.00K | -39.00K | -39.00K | -24.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -2.12M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 11.00M | 7.15M | -4.94M | 8.95M | 7.53M |
| Cash from Investing | 10.87M | 7.11M | -4.98M | 8.91M | 5.39M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 0.00 |
| Issuance of Common Stock | 0.00 | 0.00 | 35.00K | 190.00K | 57.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -5.00M | -- | -- | -- |
| Cash from Financing | 0.00 | -5.00M | 35.00K | 190.00K | 57.00K |
| Foreign Exchange rate Adjustments | 222.00K | -60.00K | -241.00K | 310.00K | -249.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.54M | -5.22M | -13.92M | 1.06M | -880.00K |